The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05935098
Recruitment Status : Recruiting
First Posted : July 7, 2023
Last Update Posted : May 31, 2024
Sponsor:
Information provided by (Responsible Party):
BeiGene

Brief Summary:
This study aims to test the safety, tolerability, and preliminary anti-tumor activity of BGB-A3055, either alone or in combination with Tislelizumab in participants with advanced or metastatic solid tumors.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumor Metastatic Solid Tumor Solid Tumor Drug: BGB-A3055 Drug: Tislelizumab Phase 1

Detailed Description:

The primary objective of the study is to assess the safety and tolerability of BGB-A3055 alone or in combination with Tislelizumab during dose escalation and to determine the recommended dose for expansion. During dose expansion, the primary objective will be to assess preliminary anti-tumor activity and further characterize the safety of the recommended dose for expansion.

. Around 318 participants will be enrolled in this study, and they will be assigned to different treatment groups. Both the participants and their doctors will be aware of which treatment group they are assigned to throughout the study.

The treatments, BGB-A3055 alone or in combination with Tislelizumab, will be administered intravenously to evaluate their safety and determine the highest dose that can be tolerated by participants. The study will be conducted at multiple medical centers worldwide. The expected duration of participation in this study is two years. Treatment will continue until participants no longer receive any benefits from the drugs, experience excessive side effects, or decide to withdraw their consent.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 318 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors
Actual Study Start Date : August 21, 2023
Estimated Primary Completion Date : February 2025
Estimated Study Completion Date : February 2025

Arm Intervention/treatment
Experimental: Phase 1a Part A: Dose Escalation (BGB-A3055 Monotherapy)
Different groups of participants will receive increasing doses of BGB-A3055 alone to determine the most appropriate dosage levels.
Drug: BGB-A3055
Administered intravenously

Experimental: Phase 1a Part B: Dose Escalation (BGB-A3055 + tislelizumab)
Different groups of participants will receive increasing doses of BGB-A3055 in combination with tislelizumab to determine the most appropriate dosage levels.
Drug: BGB-A3055
Administered intravenously

Drug: Tislelizumab
Administered intravenously
Other Name: BGB-A317

Experimental: Phase 1b (Dose Expansion):
Participants will receive the recommended dose for expansion phase (RDFE) of BGB-A3055 in combination with tislelizumab to provide additional information on the safety, tolerability, and potential benefits of the recommended dose.
Drug: BGB-A3055
Administered intravenously

Drug: Tislelizumab
Administered intravenously
Other Name: BGB-A317




Primary Outcome Measures :
  1. Phase 1a: Number of participants with adverse events (AEs) [ Time Frame: Up to 2 Years ]
    Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including laboratory values, and NCI-CTCAE v5.0.

  2. Phase 1a: Maximum tolerated dose (MTD) or maximum administered dose (MAD) of BGB-A3055 [ Time Frame: Up to 2 Years ]
    The highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 30%

  3. Phase 1a: Recommended dose for expansion (RDFE) of BGB-A3055 [ Time Frame: Up to 2 Years ]
    The RDFEs of BGB-A3055, alone and in combination with tislelizumab will be determined based on relevant data.

  4. Phase 1b (Dose Expansion): Objective Response Rate (ORR) [ Time Frame: Up to 2 Years ]
    Defined as the proportion of participants with best overall response (BOR) of a complete response (CR) or partial response (PR) as determined from tumor assessments by the investigators per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1


Secondary Outcome Measures :
  1. Phase 1a (Dose Escalation): Objective Response Rate (ORR) [ Time Frame: Up to 2 Years ]
    ORR is defined as the percentage of participants with partial or complete response, as determined from tumor assessments by the investigators per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

  2. Time to Response (TTR) [ Time Frame: Up to 2 Years ]
    Defined as the time from the date of the first administration of study drug(s) to the first determination of an objective response.as determined from tumor assessments by the investigators per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

  3. Duration of Response (DoR) [ Time Frame: Up to 2 Years ]
    Defined as the time from the first determination of an objective response until the first documentation of disease progression or death due to any cause, whichever occurs first, as determined from tumor assessments by the investigators per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

  4. Disease Control Rate (DCR) [ Time Frame: Up to 2 Years ]
    Defined as the proportion of participants with BOR of a CR, PR, or stable disease as determined from tumor assessments by the investigators per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

  5. Clinical Benefit Rate (CBR) [ Time Frame: Up to 2 Years ]
    Defined as the proportion of participants with BOR of a CR, PR, or stable disease lasting ≥ 24 weeks as determined from tumor assessments by the investigators per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

  6. Number of participants with anti-drug antibodies (ADAs) against BGB-A3055 [ Time Frame: Up to 2 Years ]
  7. Number of participants with anti-drug antibodies (ADAs) against tislelizumab [ Time Frame: Up to 2 Years ]
  8. Serum concentration of BGB-A3055 at specified time points [ Time Frame: Up to 2 Years ]
  9. Phase 1b (Dose Expansion): Progression-Free Survival (PFS) [ Time Frame: Up to 2 Years ]
    defined as the time from the date of the first administration of study drug(s) to the date of the first documentation of disease progression or death due to any cause, whichever occurs first, as determined from tumor assessments by the investigators per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

  10. Phase 1b (Dose Expansion): Number of participants with adverse events (AEs) [ Time Frame: Up to 2 Years ]
    Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including laboratory values, physical examination findings, and electrocardiogram results.

  11. Phase 1b (Dose Expansion) CCR8 expression [ Time Frame: Up to 2 Years ]
    Evaluated from participant-derived tumor tissue(s) obtained before and/or after treatment with BGB-A3055 in combination with tislelizumab, and their association with clinical efficacy.

  12. Phase 1b (Dose Expansion) PD-L1 expression [ Time Frame: Up to 2 Years ]
    Evaluated from participant-derived tumor tissue(s) obtained before and/or after treatment with BGB-A3055 in combination with tislelizumab, and their association with clinical efficacy.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age≥18 years on the day of signing the informed consent form (ICF) (or the legal age of consent in the jurisdiction in which the study is taking place, whichever is older).
  2. All participants are also required to demonstrate an ECOG Performance Status score of≤1 and have adequate organ function.
  3. Participants with histologically confirmed advanced or metastatic solid tumors associated with high CCR8 and who have previously received available standard systemic therapy or for whom treatment is not available or not tolerated and could not receive any prior therapy targeting CCR8.
  4. >=1 Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
  5. Participants should be able to provide the archival formalin-fixed paraffin-embedded (FFPE) tumor tissues (as block or unstained slides) or fresh biopsy if there is no archival tissue at baseline. For selected cohorts, participants should be willing to provide post-treatment fresh biopsy at specified timepoints.

Exclusion Criteria:

  1. Active leptomeningeal disease or uncontrolled, untreated brain metastasis.
  2. Active autoimmune diseases or history of autoimmune diseases that may relapse
  3. Any malignancy ≤ 3 years before the first dose of study drug(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast).
  4. Untreated chronic hepatitis B or chronic HBV carriers with HBV DNA ≥ 500 IU/mL (or ≥ 2500 copies/mL) at screening. Participants with active hepatitis C, and participants with HIV infection.

    Note: Inactive hepatitis B surface antigen (HBsAg) carriers, treated and stable hepatitis B can be enrolled. Participants with a negative HCV antibody test result at screening or a positive HCV antibody test result followed by a negative HCV RNA test result at screening are eligible to participate. Participants with treated HIV infection may be included if certain criteria are met.

  5. History of interstitial lung disease, noninfectious pneumonitis, or uncontrolled lung diseases including pulmonary fibrosis, or acute lung diseases .

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05935098


Contacts
Layout table for location contacts
Contact: BeiGene 1 (877) 828-5568 clinicaltrials@beigene.com

Locations
Layout table for location information
United States, Iowa
University of Iowa Hospitals and Clinics Recruiting
Iowa City, Iowa, United States, 52242
United States, New Jersey
John Theurer Cancer Center Hackensack University Medical Center Recruiting
Hackensack, New Jersey, United States, 07601
United States, Texas
Next Dallas Recruiting
Irving, Texas, United States, 75039
Australia, New South Wales
Chris Obrien Lifehouse Recruiting
Camperdown, New South Wales, Australia, 2050
Australia, Queensland
Icon Cancer Care South Brisbane Recruiting
South Brisbane, Queensland, Australia, 4101
Australia, Western Australia
Linear Clinical Research Recruiting
Nedlands, Western Australia, Australia, 6009
France
Centre de Lutte Contre Le Cancer Institut Bergonie Recruiting
Bordeaux, France, 33076
Institut Curie Recruiting
Paris, France, 75005
Ico Site Rene Gauducheau Recruiting
SaintHerblain, France, 44805
Sponsors and Collaborators
BeiGene
Investigators
Layout table for investigator information
Study Director: Study Director BeiGene
Layout table for additonal information
Responsible Party: BeiGene
ClinicalTrials.gov Identifier: NCT05935098    
Other Study ID Numbers: BGB-A317-A3055-101
2023-505322-34-00 ( Registry Identifier: CTIS )
First Posted: July 7, 2023    Key Record Dates
Last Update Posted: May 31, 2024
Last Verified: May 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by BeiGene:
BGB-A3055
Tislelizumab
Advanced solid tumors
Safety monitoring
Monoclonal antibody
Preliminary antitumor activity
Metastatic cancer
Metastatic Solid Tumor
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Tislelizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents